Wokvac Vaccine
Residual Disease
H. Lee Moffitt Cancer Center and Research InstitutevaccinePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
10 Active assets in the Residual Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
DEXAMETHASONE University of Chicago | Phase 2 | B |
cc-5013 University of Chicago | Phase 2 | B |
mln9708 University of Chicago | Phase 2 | B |
Datopotamab Deruxtecan UNC Lineberger Comprehensive Cancer Center | Phase 2 | CCC |
Epirubicin Dartmouth-Hitchcock Medical Center | Phase 1/2 | CC |
View all 13 →
Same molecule, other indications
Wokvac Vaccine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →